Cabaletta Bio is getting set to launch a clinical trial testing its cell therapy resecabtagene autoleucel (rese-cel) in people with relapsing and progressive forms of multiple sclerosis (MS).

Stem cells have shown some promise in treating the neural damage that MS causes. Research on stem cells in MS has included test-tube studies, animal studies, and some human studies. Researchers ...

In MS, immune system cells mistakenly attack myelin. With stem cell treatment, doctors use chemotherapy to destroy these existing immune cells. Then, they introduce the new stem cells, which are ...

PMN in the mastitic milk were counted using Gram staining. Further, somatic cell counts (SCC), interleukin (IL)-6, IL-8, tumor necrosis factor (TNF)-α, IL-10 and serum amyloid A (SAA) concentrations ...

Gene set enrichment analysis was used to identify molecular pathways altered in MS. In the proteomics analysis, albumin quotient, age, immunoglobulin G (IgG) synthesis in CSF, cell count ...

A distinct microRNA (miRNA) signature in the cerebrospinal fluid (CSF) of people with multiple sclerosis (MS) has been identified, according to results of a study published in Neurology ...

We find that homeodomain genes are expressed in stripes along the anterior-posterior axis, as early as the 28-cell stage. Interestingly, each founder-cell lineage – AB, MS, C and E – establishes its ...

Multiple sclerosis (MS) has been classically categorized as an autoimmune disease in which self-reactive T CD4+ (Th1/Th17), T CD8+, and B cells attack the central nervous system (CNS) and cause ...